Diagnostic value of plasmin-α2-plasmin inhibitor complex in patients with malignant tumor and venous thromboembolism.

IF 0.3 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Hippokratia Pub Date : 2023-04-01

J Liu, F Wang, Y Wang, S S He, Y Y Wang, L H Wei

{"title":"Diagnostic value of plasmin-α2-plasmin inhibitor complex in patients with malignant tumor and venous thromboembolism.","authors":"J Liu, F Wang, Y Wang, S S He, Y Y Wang, L H Wei","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: We aimed to evaluate in this study the diagnostic value of the plasmin-α2-plasmin inhibitor complex in patients with malignant tumors and venous thromboembolism (VTE).Methods: A total of 58 patients with confirmed malignant tumors and VTE were selected, and their plasma samples were collected within 24 hours after VTE diagnosis. We also selected 60 patients with malignant tumors who were hospitalized at the same time and did not have VTE following imaging examination. Their plasma samples were collected within 24 hours after admission and were compared to those of the VTE group concerning the levels of plasmin-α2-plasmin inhibitor (PIC), thrombin-antithrombin complex (TAT), tissue-type plasminogen activator-inhibitor complex (tPAI-C), and thrombomodulin (TM). We used the receiver operator characteristic (ROC) curve to evaluate the diagnostic efficacy of each index regarding malignant tumors accompanied by VTE.Results: PIC, TAT, and tPAI-C were significantly higher in the group with malignant tumors and VTE compared to the group with malignant tumors without thrombosis (p =0.010, p =0.001, and p =0.003, respectively). In contrast, we found no significant difference in TM levels between the two groups (p =0.483). The area under the curve (AUC) of PIC, TAT, and tPAI-C regarding patients with malignant tumors and VTE was 0.852, 0.636, and 0.655, respectively, demonstrating diagnostic values for those cancer patients suffering VTE. PIC had the highest diagnostic efficiency in those patients with malignant tumors and VTE, while the AUC of TM was 0.537, so its diagnostic value for VTE-complicated malignant tumors was limited.Conclusion: PIC has a sufficient value for the early diagnosis of VTE in patients with malignant tumors. HIPPOKRATIA 2023, 27 (2):37-40.","PeriodicalId":50405,"journal":{"name":"Hippokratia","volume":"27 2","pages":"37-40"},"PeriodicalIF":0.3000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268312/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hippokratia","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We aimed to evaluate in this study the diagnostic value of the plasmin-α2-plasmin inhibitor complex in patients with malignant tumors and venous thromboembolism (VTE).

Methods: A total of 58 patients with confirmed malignant tumors and VTE were selected, and their plasma samples were collected within 24 hours after VTE diagnosis. We also selected 60 patients with malignant tumors who were hospitalized at the same time and did not have VTE following imaging examination. Their plasma samples were collected within 24 hours after admission and were compared to those of the VTE group concerning the levels of plasmin-α2-plasmin inhibitor (PIC), thrombin-antithrombin complex (TAT), tissue-type plasminogen activator-inhibitor complex (tPAI-C), and thrombomodulin (TM). We used the receiver operator characteristic (ROC) curve to evaluate the diagnostic efficacy of each index regarding malignant tumors accompanied by VTE.

Results: PIC, TAT, and tPAI-C were significantly higher in the group with malignant tumors and VTE compared to the group with malignant tumors without thrombosis (p =0.010, p =0.001, and p =0.003, respectively). In contrast, we found no significant difference in TM levels between the two groups (p =0.483). The area under the curve (AUC) of PIC, TAT, and tPAI-C regarding patients with malignant tumors and VTE was 0.852, 0.636, and 0.655, respectively, demonstrating diagnostic values for those cancer patients suffering VTE. PIC had the highest diagnostic efficiency in those patients with malignant tumors and VTE, while the AUC of TM was 0.537, so its diagnostic value for VTE-complicated malignant tumors was limited.

Conclusion: PIC has a sufficient value for the early diagnosis of VTE in patients with malignant tumors. HIPPOKRATIA 2023, 27 (2):37-40.

本刊更多论文

恶性肿瘤和静脉血栓栓塞患者中的凝血酶-α2-凝血酶抑制剂复合物的诊断价值。

研究目的本研究旨在评估 plasmin-α2-plasmin 抑制剂复合物在恶性肿瘤合并静脉血栓栓塞（VTE）患者中的诊断价值：方法：选取 58 例确诊为恶性肿瘤合并 VTE 的患者，在 VTE 确诊后 24 小时内采集血浆样本。我们还选择了 60 名同时住院的恶性肿瘤患者，他们在影像学检查后未发现 VTE。我们在入院后 24 小时内采集了他们的血浆样本，并将其与 VTE 组的血浆样本进行了比较，比较了血浆中的plasmin-α2-plasmin 抑制剂（PIC）、凝血酶-抗凝血酶复合物（TAT）、组织型纤溶酶原激活剂-抑制剂复合物（tPAI-C）和血栓调节蛋白（TM）的水平。我们使用接收器操作特征曲线（ROC）评估了各指标对伴有 VTE 的恶性肿瘤的诊断效果：结果：与恶性肿瘤伴有 VTE 组相比，恶性肿瘤伴有 VTE 组的 PIC、TAT 和 tPAI-C 明显更高（分别为 p =0.010、p =0.001、p =0.003）。相比之下，我们发现两组之间的 TM 水平无明显差异（p =0.483）。PIC、TAT 和 tPAI-C 对恶性肿瘤和 VTE 患者的曲线下面积（AUC）分别为 0.852、0.636 和 0.655，显示了对 VTE 患者的诊断价值。PIC 对恶性肿瘤合并 VTE 患者的诊断效率最高，而 TM 的 AUC 为 0.537，因此其对 VTE 并发恶性肿瘤的诊断价值有限：结论：PIC 对恶性肿瘤患者 VTE 的早期诊断具有足够的价值。Hippokratia 2023, 27 (2):37-40.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hippokratia MEDICINE, GENERAL & INTERNAL-

CiteScore

1.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Hippokratia journal is a quarterly issued, open access, peer reviewed, general medical journal, published in Thessaloniki, Greece. It is a forum for all medical specialties. The journal is published continuously since 1997, its official language is English and all submitted manuscripts undergo peer review by two independent reviewers, assigned by the Editor (double blinded review process). Hippokratia journal is managed by its Editorial Board and has an International Advisory Committee and over 500 expert Reviewers covering all medical specialties and additionally Technical Reviewers, Statisticians, Image processing Experts and a journal Secretary. The Society “Friends of Hippokratia Journal” has the financial management of both the printed and electronic edition of the journal.